AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
55,000
Employees55,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
55,000
Employees55,000

ABBV Key Statistics

Market cap
304.21B
Market cap304.21B
Price-Earnings ratio
75.24
Price-Earnings ratio75.24
Dividend yield
3.50%
Dividend yield3.50%
Average volume
10.49M
Average volume10.49M
High today
$180.00
High today$180.00
Low today
$170.68
Low today$170.68
Open price
$177.66
Open price$177.66
Volume
2.53M
Volume2.53M
52 Week high
$218.66
52 Week high$218.66
52 Week low
$153.58
52 Week low$153.58

ABBV News

TipRanks 1d
AbbVie price target raised to $241 from $239 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on AbbVie (ABBV) to $241 from $239 and keeps an Overweight rating on the shares. The firm ad...

TipRanks 2d
AbbVie assumed with a Neutral at Goldman Sachs

Goldman Sachs analyst Asad Haider assumed coverage of AbbVie (ABBV) with a Neutral rating and $194 price target The company’s “strong” growth for “commercial po...

Simply Wall St 3d
AbbVie Showcases Cancer Treatment Advancements at AACR Annual Meeting

has been actively advancing its oncology portfolio with recent presentations at the AACR Annual Meeting, showcasing developments like ABBV-969 and ABBV-514, bot...

AbbVie Showcases Cancer Treatment Advancements at AACR Annual Meeting

Analyst ratings

62%

of 29 ratings
Buy
62.1%
Hold
34.5%
Sell
3.4%

More ABBV News

TipRanks 5d
Salesforce, Block, AbbVie, Applied Materials, Oracle: Insider Moves Unveiled!

Insiders have been trading these 5 stocks: ((CRM)), ((XYZ)), ((ABBV)), ((AMAT)) and ((ORCL)). Here is a breakdown of their recent trades and their value. In a...

TipRanks 7d
AbbVie sees Q1 adjusted EPS with expenses $2.34-$2.38, consensus $2.51

In a regulatory filing, AbbVie (ABBV) disclosed that reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.